FTSE 100 Live: FTSE 100 extends losses as oil tops $100 and inflation fears mount

FTSE 100 fell 1.12% to 10,691. Broker moves: HSBC downgraded Burberry to 'hold' with 1,200p target; RBC initiated AstraZeneca at 'outperform' with 14,500p target. Oil prices topped $100, raising inflation concerns. Brent crude rose 2.93% to $100.85. FTSE 250 also saw mixed broker activity.

Original reporting
Published Sep 9, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMacro economy
Primary signal
$AZN
Bullish
medium confidence
Mentioned
$AZN · $CCC
Relevance
4/10
AlphAI data visualization · based on proactiveinvestors.co.uk
Decision brief

The 30-second read

$AZNBullishLow
01

Why it matters

The tradable signal is mostly macro and positioning. Single-name items include Burberry’s downgrade, AstraZeneca’s RBC initiation, and Aberdeen’s chair-designate appointment, but the broader index move is attributed to oil and inflation dynamics.

02

Market read

Traders should treat this primarily as a macro-driven risk-off tape, with selective single-name catalysts from broker actions and governance news.

03

What to watch

The piece notes investors await a US Treasury bond buyback announcement, which could quickly change rate expectations and reverse parts of the equity move.

Relevance 4/10Novelty 3/10Timing: intraday, during the FTSE 100 session as oil tops $100 and broker notes hit

Background

This is a London market wrap describing FTSE 100 weakness, broker rating changes in select FTSE names, and macro drivers including Brent crude above $100 and inflation fears.

Company-level read

Ticker impact

$AZNBullishMedium confidence
Context

RBC began coverage of AstraZeneca at 'outperform' with a 14,500p target, introducing a fresh analyst stance for AZN.

Expected impact

May provide relative support versus other FTSE names, but likely muted by broad index risk from oil and inflation.

Evidence & confidence

The catalyst is a new coverage initiation with a stated target, yet the article frames the broader move as macro-driven.

$CCCNeutralLow confidence
Context

Computacenter (FTSE 250) saw opposing broker calls, signaling mixed sentiment for CCC during the session.

Expected impact

Near-term volatility likely higher, with direction uncertain given 'opposing calls' framing.

Evidence & confidence

The article does not specify the direction or magnitude of each call, only that they were mixed.

Market effects

Oil above $100 is framed as the main driver, feeding inflation and rate-elevated-for-longer concerns that pressure retailers and energy-intensive businesses.

UK equities are trading near session lows with US futures subdued, suggesting cross-Atlantic risk sentiment remains cautious.

Middle East supply disruption risk and inflation expectations are the transmission channels to global equities and rates.

Counterpoint

The article’s oil-inflation narrative may be overextended intraday; commodity strength could keep some energy-linked names supported even if the index drifts lower.

Key entities

  • FTSE 100

    UK blue-chip benchmark described as down 1.12% near the session low, driven by oil and inflation fears.

  • Brent crude

    Brent is reported above $100, with Middle East tensions cited as the supply-risk driver.

  • Burberry Group

    Broker cut to 'hold' with a 1,200p target.

  • AstraZeneca

    RBC initiated coverage at 'outperform' with a 14,500p target.

  • Aberdeen Group

    Appointed Torbjörn Magnusson as chair-designate, pending regulatory approval.

Related articles

$AZNMedAI 8/10

Enhertu: NICE Approval Expands NHS Breast Cancer Care

AstraZeneca and Daiichi Sankyo's Enhertu received NICE approval for HER2-positive breast cancer treatment. The drug, priced at £1,455 per 100mg vial, was initially rejected due to cost but gained approval after NICE's valuation methodology change. It extends patient lifespans by an average of seven months.